The CDC’s latest weekly influenza surveillance report shows activity rising across much of the US, with H1N1 continuing to dominate and hospitalizations increasing.
Seasonal influenza activity is increasing in many parts of the US and is higher than typically observed at this time of year, according to the CDC’s latest weekly surveillance report for Week 44, which ended Nov 7.
Clinical laboratories nationwide tested 52,287 specimens during the week, and 5,911 (11.3%) were positive for influenza. Flu test positivity rose nationally and in eight of the 10 US Department of Health and Human Services regions. It remained stable in Region 8 and declined in Region 9, which the CDC attributes to possibly incomplete reporting.
Since Oct 4 (Week 40), clinical labs have tested 309,131 specimens, with 24,324 (7.9%) testing positive. Influenza A accounted for 99.2% of positive specimens in Week 44.
The CDC cautioned that an earlier increase in activity does not necessarily lead to a higher seasonal peak or greater overall severity. Its preliminary in-season assessment classifies severity as low across all age groups, though the agency noted the assessment may change as activity climbs.
H1N1 Predominates, With Growing Genetic Diversity
Public health laboratories reported 680 positive influenza viruses in Week 44, of which 670 were influenza A and 10 were influenza B. Of the 460 influenza A viruses subtyped, 455 (98.9%) were A(H1N1)pdm09 and 5 (1.1%) were A(H3N2). Since Week 21 (the week ending May 30), 83.4% of reported influenza A viruses have been A(H1N1)pdm09, most of them in the D.3.1.1 HA subclade.
The CDC noted that recently circulating D.3.1.1 viruses have divided into distinct groups with different genetic changes in their HA genes, and that there is more genetic diversity among co-circulating A(H1N1)pdm09 viruses than previously seen. The agency said it is too early to know which viruses may predominate or whether there could be implications for vaccine effectiveness this season.
Of the 764 influenza viruses genetically characterized since May 24, 555 were A(H1N1)pdm09, and 554 of those (99.8%) belonged to the D.3.1.1 subclade. Among 109 A(H3N2) viruses, 104 (95.4%) were subclade K. The 100 B/Victoria viruses were spread across several subclades, led by C.5.6.1 (48.0%) and C.3.1 (40.0%).
Vaccine Match and Antiviral Susceptibility
Antigenic testing showed most circulating viruses are well recognized by antisera to the 2026-2027 vaccine reference viruses. Of 147 A(H1N1)pdm09 viruses characterized by hemagglutination inhibition, 140 (95.2%) were well recognized by antisera to the A/Missouri/11/2025-like reference virus. All 35 A(H3N2) viruses and all 33 B/Victoria viruses tested were well recognized by antisera to their respective vaccine reference viruses.
For antiviral susceptibility, the CDC tested 758 viruses collected since May 24 against oseltamivir, peramivir, and zanamivir, and 725 against baloxavir. Eight A(H1N1)pdm09 viruses (1.1% of all viruses tested) showed reduced inhibition by oseltamivir and carried the NA-I223V and NA-S247N substitutions. No viruses showed reduced inhibition by peramivir or zanamivir, and none showed decreased susceptibility to baloxavir.
Outpatient, Hospital, and Mortality Indicators
Outpatient respiratory illness is above baseline. Nationally, 3.2% of ILINet patient visits were for influenza-like illness in Week 44, above the national baseline of 2.9%. Emergency department visits with a discharge diagnosis of influenza reached 2.2%, and the percentage rose in every HHS region except Region 7, where it was stable. The CDC’s ILI activity map shows one jurisdiction at a very high level, six at a high level, and nine at a moderate level.
Hospitalization data point to rising severe disease, particularly among older adults. Hospitals reported 9,584 laboratory-confirmed, influenza-associated admissions to the National Healthcare Safety Network in Week 44, a rate of 2.8 per 100,000 population. FluSurv-NET recorded 3,262 laboratory-confirmed influenza hospitalizations between Oct. 4 and Nov. 7, for a cumulative rate of 8.7 per 100,000. The highest rate was among adults 65 and older, at 28.0 per 100,000.
Influenza accounted for 0.4% of deaths in Week 44, a stable figure that has trended upward over the past eight weeks. The CDC received reports of two pediatric deaths from the current season this week, bringing the season total to five. One death from the 2025-2026 season was also reported, raising that season’s pediatric death total to 203.
The CDC estimates that at least 2.6 million illnesses, 36,000 hospitalizations, and 2,100 deaths have been associated with flu so far this season. Its FluSight forecasts predict a likely national increase in flu hospital admissions, ranging from 8,300 to 34,400, for the week ending Nov. 28. They also predict that 1.8% to 7.7% of emergency department visits will be due to flu.
Novel Influenza Surveillance
No new confirmed human infections with a novel influenza virus were reported to the CDC as of Nov 7. Public health laboratories have detected four H5-positive specimens since Oct 4, none of them in Week 44. The CDC noted that these figures reflect specimens tested rather than human cases.
The CDC continues to recommend annual influenza vaccination for everyone 6 months and older and says prescription antivirals should be started as early as possible, especially for patients at higher risk of complications. All data are preliminary and may change as more reports are received.
ID 119692457 © Jarun011 | Dreamstime.com